Thomas Ulmer

Director of Finance/CFO at PYC THERAPEUTICS LIMITED

47 year

Health Technology

Consumer Services

Profile

Thomas Ulmer is currently Non-Executive Director at Aravax Pty Ltd. since 2020 and Chief Financial Officer at PYC Therapeutics Ltd. starting in 2026.
Formerly, Mr. Ulmer was Co-Managing Director at Immatics Biotechnologies GmbH from 2018 to 2020, Head-Planning, Forecasting & Resource Allocation at Merck KGaA from 2012 to 2016, Chief Financial Officer at Immatics NV, and Chief Financial Officer at Cell Therapies Pty Ltd. Education includes an MBA from the University of Giessen.

Thomas Ulmer active positions

Companies	Position	Start
PYC THERAPEUTICS LIMITED	Director of Finance/CFO	06/07/2026
Aravax Pty Ltd. Aravax Pty Ltd. BiotechnologyHealth Technology Develops treatments for peanut allergies	Director/Board Member	31/10/2020

All active positions of Thomas Ulmer

Former positions of Thomas Ulmer

Companies	Position	End
Immatics Biotechnologies GmbH Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer	Chief Executive Officer	11/02/2020
MERCK KGAA	Corporate Officer/Principal	30/06/2016
Cell Therapies Pty Ltd.	Director of Finance/CFO	-
IMMATICS N.V.	Director of Finance/CFO	-

See the detail of Thomas Ulmer's experience

Training of Thomas Ulmer

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Thomas Ulmer's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	7
Merck KGaA Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products	Health Technology
PYC Therapeutics Ltd. PYC Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Provides discovery and development of peptide based therapeutic candidates	Health Technology
Immatics Biotechnologies GmbH Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer	Health Technology
University of Giessen University of Giessen Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Cell Therapies Pty Ltd.
Aravax Pty Ltd. Aravax Pty Ltd. BiotechnologyHealth Technology Develops treatments for peanut allergies	Health Technology
Immatics NV Immatics NV Pharmaceuticals: MajorHealth Technology Engages in developing immunotherapies for cancer treatments	Health Technology